By bridging the gap between theoretical logic and practical application, the syllabus fosters the technical proficiency and ...

If you’re reading this, that means you’ve successfully made it through 2025! Allow us to be the first to congratulate you — ...

A drug for autoimmune disease Sjögren's syndrome, picked up by Novartis when it bought MorphoSys for $2.9 billion last year, has hit the target in a pair of phase 3 trials. Ianalumab (VAY736), a drug ...